Table 1.

Degradation products in EDL muscle following fatiguing contractions

		Fatigue Group
Cx, µmol/g	Treatment	None	LOW	MOD	HIGH
IMP*^	Control	0.087 ± 0.081	0.183 ± 0.092	0.862 ± 0.487	2.555 ± 0.783
	RNAi	0.062 ± 0.045	0.134 ± 0.114	0.601 ± 0.405	1.923 ± 0.888
Inosine*^	Control	-	0.005 ± 0.004	0.026 ± 0.021	0.063 ± 0.030
	RNAi	-	0.004 ± 0.004	0.030 ± 0.023	0.047 ± 0.027
Hypoxanthine*	Control	-	-	0.007 ± 0.005	0.020 ± 0.008
	RNAi	-	-	0.009 ± 0.007	0.019 ± 0.008
Xanthine*	Control	-	-	-	0.005 ± 0.003
	RNAi	-	-	-	0.006 ± 0.005

IMP, inosine monophosphate; iRNA, inhibitory microRNA. For each group, control and RNAi muscles were taken from the same animal. Data are represented as means ± SD, n = 6 males and 3 females per group.

^*P < 0.05 main effect of duty cycle; ^P < 0.05 main effect of treatment (RNAi); (-) not detectable.